Wenfeng Fang

New Capabilities

Presented the OptiTROP-Lung04 final OS analysis at ESMO 2026

Patients with EGFR-mutant lung cancer whose disease progressed on targeted therapy lived a median 25.9 months on sac-TMT, against 17.4 months on platinum doublet chemotherapy. Those are the final overall survival figures from the 376-patient OptiTROP-Lung04 trial, presented at the 2026 ESMO Congress in Madrid by Wenfeng Fang of Sun Yat-sen University Cancer Center.

Updated Oct 27